lipid nanoparticle

SM-102 is the only ionizable amino cationic lipid currently clinically approved for RNA therapeutics and can be used to synthesize lipid nanoparticles (LNPs). It shows potential in the development of LNPs for the delivery of mRNA-based vaccines.

1,2-Distearoyl-sn-glycero-3-phosphorylcholine (L-ALPHA-PHOSPHATIDYLCHOLINE, DISTEAROYL) is a cylindrical-shaped lipid used to synthesize liposomes. 1,2-Distearoyl-sn-glycero-3-phosphorylcholine (L-ALPHA-PHOSPHATIDYLCHOLINE, DISTEAROYL) is the lipid component in the lipid nanoparticle (LNP) system.

Heptadecan-9-yl 8-((6-(decyloxy)-6-oxohexyl)(2-hydroxyethyl)amino)octanoate is employed in lipid nanoparticle (LNP) delivery systems for mRNA vaccine delivery [1].

CD19 car mRNA-LNP, a lipid nanoparticle (LNP) encapsulating CD19 car mRNA, is instrumental in assessing RNA delivery, translation efficacy, and cell viability among other applications. This compound is pivotal for chimeric antigen receptor T cell immunotherapy (CAR-CD19), leveraging the CD19 molecule - a critical membrane antigen expressed by B cells (i.e., leukocyte differentiation antigen) that plays a significant role in their proliferation, differentiation, activation, and antibody production, as well as enhancing BCR signal transduction [1] [2].

C13-113-tetra tail, a cationic lipid-like compound, features a polar amino alcohol head group, a tertiary amine linker, and four hydrophobic carbon-13 tails. It can be formulated into a lipid nanoparticle (LNP).

DSPE-PEG(2000)-amine is a PEGylated derivative of 1,2-distearoyl-sn-glycero-3-PE . It has been used in the synthesis of solid lipid and thermosensitive liposomal nanoparticles for the delivery of anticancer agents.1,2,3DSPE-PEG(2000)-amine has also been used in the synthesis of fluorescein isothiocyanate-loaded mesoporous silica nanoparticles for imaging applications.4It can be conjugated to a variety of functional molecules for improved cellular targeting and uptake of DSPE-PEG(2000)-amine-containing nanoparticles.4,5 1.Sloat, B.R., Sandoval, M.A., Li, D., et al.In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticlesInt. J. Pharm.409(1-2)278-288(2011) 2.Abd-Rabou, A.A., Bharali, D.J., and Mousa, S.A.Taribavirin and 5-fluorouracil-loaded pegylated-lipid nanoparticle synthesis, p38 docking, and antiproliferative effects on MCF-7 breast cancerPharm. Res.35(4)76(2018) 3.Affram, K., Udofot, O., Singh, M., et al.Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imagingPLoS One12(9):e0815116(2017) 4.Wang, L.-S., Wu, L.-C., Lu, S.-Y., et al.Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: Improved water suspensibility and decreased nonspecific protein bindingACS Nano4(8)4371-4379(2010) 5.Wen, X., Wang, K., Zhao, Z., et al.Brain-targeted delivery of trans-activating transcriptor-conjugated magnetic PLGA/lipid nanoparticlesPLoS One9(9):e106652(2014)

TCL053, an ionizable lipid carrier, efficiently facilitates the introduction of active components, particularly nucleic acids, into cells. In combination with Dipalmitoylphosphatidylcholine (DPPC), Polyethylene glycol dimyristoyl glycerol (PEG-DMG), and cholesterol, TCL053 composes a lipid nanoparticle (LNP) system capable of delivering Cas9 mRNA and sgRNA into skeletal muscle [1] [2].

LNP Lipid-4 (Compound 8-8) is a lipid compound integral to the synthesis of lipid nanoparticle compositions, demonstrating potential for the transport of biologically active substances [1].

Genevant CL1 is a lipid that can be used for mRNA lipid nanoparticle (LNP) vaccine delivery [1] .

Cholesteryl oleate (Cholesteryl cis-9-octadecenoate) is a cholesteryl ester. Cholesteryl oleate can be used to synthesize solid lipid nanoparticles which is a nanoparticle-based gene therapy approach.

306-N16B is a lipid nanoparticle designed for the systemic co-delivery of Cas9 mRNA and sgRNA, facilitating the transport of mRNA to pulmonary endothelial cells. This compound is advantageous for research focused on genome editing-based therapies [1].

COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) formulated with the novel coronavirus pneumonia spike protein, positioned on the membrane surface. It is designed for applications such as RNA delivery, translation efficiency, and cell viability assessment. This spike protein facilitates the COVID-19 virus's entry into host cells by binding to cell membrane receptors and enabling membrane fusion, making it a critical focal point for host neutralizing antibodies and vaccine development [1].

CD19 car circRNA-LNP, a lipid nanoparticle containing CD19 car circRNA, is designed for applications in RNA delivery, translation efficiency, and cell viability assessment. This compound is utilized in chimeric antigen receptor T cell immunotherapy (CAR-CD19), leveraging CD19 car, a chimeric antigen receptor that targets CD19. CD19, a CD molecule found on B cells (i.e., leukocyte differentiation antigen), plays a crucial role in B cell proliferation, differentiation, activation, and antibody production by facilitating BCR signal transduction [1] [2].

BAMEAO16B is a lipid nanoparticle that incorporates disulfide bonds for efficient delivery of Cas9 mRNA and sgRNA into cells. In the intracellular environment, BAMEAO16B responds to reduction by releasing RNA, facilitating genome editing. This compound is valuable for gene editing research purposes.

C13-113-tri tail, a cationic lipid-like compound, features a polar amino alcohol head group, three hydrophobic carbon-13 tails, and a tertiary amine linker. It is capable of being formulated into a lipid nanoparticle (LNP).